Vor Biopharma Inc.
VORHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeVor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The $989.4M market capitalization puts VOR squarely in small-cap range for its industry. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Market Cap
$989.4M
Beta
1.78
P/E (TTM)
0.10
P/E (Fwd)
-4.98
EPS (TTM)
$180.37
EPS (Fwd)
$-3.67
ROE
—
ROA
-21.4%
Cash
$466.1M
Total Debt
$2.9M
Free CF
-$79.5M
52W Change
-35.1%
Annual Financials
Cash vs Debt
Where VOR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VOR finished 0.28% above its 150-day moving average ($17.99) and 5.81% above its 200-day moving average ($17.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VOR overbought or oversold?
At the October 20, 2026 close, VOR's RSI(14) was 48.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $466.1M in cash comfortably exceeding the $2.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$79.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
Vor Biopharma Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, VOR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VOR.